Welcome to our dedicated page for Bruker news (Ticker: BRKR), a resource for investors and traders seeking the latest updates and insights on Bruker stock.
Bruker Corporation (Nasdaq: BRKR) regularly issues news and updates on its activities in scientific instruments, diagnostics, superconducting technologies, and advanced research collaborations. This news page aggregates company press releases and third-party coverage so readers can review developments affecting Bruker’s analytical instruments, diagnostic solutions, and related businesses.
Recent announcements highlight multi-year orders in the Bruker Energy & Supercon Technologies (BEST) division for high-performance superconductors used in MRI magnets, including materials that support helium-free MRI magnet architectures. News items also cover orders for high-field NMR and EPR systems from leading European research institutions for materials science, battery research, and disease biology, illustrating how Bruker’s magnetic resonance systems are deployed in academic and government research environments.
Bruker’s news flow also reflects its expansion in applied mass spectrometry and diagnostics. The company has reported the consolidation of full ownership of TOFWERK AG, adding ultra-fast time-of-flight mass spectrometry for real-time air and semiconductor cleanroom monitoring, atmospheric chemistry research, exposomics, and food, flavors and fragrances testing. It has also been associated with the acquisition of AST Revolution, an in vitro diagnostics company focused on rapid antimicrobial susceptibility testing (AST) solutions built around the WAVE and Arc systems.
Investors and researchers following BRKR news can expect updates on earnings releases and financial guidance, capital structure developments such as preferred stock offerings and dividends, board and governance changes, and strategic transactions. This page is a convenient entry point for tracking how Bruker’s instruments, diagnostics, and superconducting technologies are being adopted across life sciences, applied markets, industrial and cleantech research, and semiconductor-related applications.
Bruker (Nasdaq: BRKR) will report Q1 2026 financial results before market open on Wednesday, May 6, 2026, with a conference call and webcast at 8:00 a.m. ET.
A slide presentation will be posted shortly before the webcast. Investors may join via the investor website, phone (U.S. or international), or pre-register for a personalized dial‑in and PIN. A telephone replay is available through June 6, 2026.
Bruker (Nasdaq: BRKR) will showcase new cross-platform spatial biology workflows and high‑plex datasets at AACR 2026, including GeoMx-to-CellScape, CellScape-to-CosMx, a 208-plex CellScape XR spatial proteomics dataset, the PaintScape 419-plex panel, and commercial shipments expected this quarter or summer.
These updates emphasize integrated multiomic workflows linking whole transcriptome, proteomics, and 3D genome imaging for translational oncology research.
Bruker (NASDAQ:BRKR) announced portfolio enhancements at ESCMID Global 2026 across MALDI Biotyper, IR Biotyper, MBioSEQ Ridom Typer and integration of Molzym.
Key items: MBT Easy T kit (supports up to 2,000 samples), reference libraries expanded to 5,300+ species (+600 species), IVDR and US clinical studies targeting FDA submissions in 2026, and new IR Tracker outbreak surveillance capabilities.
Bruker (Nasdaq: BRKR) launched the MyGenius PRO high-throughput, fully automated sample-to-answer PCR molecular diagnostics system in Europe on April 17, 2026.
At launch the IVDR-compliant menu includes CMV, EBV (whole blood) and BKV (urine), with additional IVDR assays planned throughout 2026. The platform was co-developed with ELITechGroup and Hitachi High-Tech (Japan: LABOSPECT GA-5).
Bruker (Nasdaq: BRKR) unveiled new NMR hardware, software, and automated workflows at ENC 2026 to boost sensitivity, throughput, and reproducibility across research and applied NMR.
Key introductions include AVANCE NEO-X electronics, Advanced Chemical Profiling 2.0, the Fourier 80 Duo 80 MHz benchtop, new standard‑bore DNP probes, the Dynamis dissolution DNP system, NMRtist AI tools, RNA NMR toolkits, 160 kHz MAS solutions, Chemspeed automation, and SciY lab digitalization software.
Bruker (Nasdaq: BRKR) announced accelerated development of its photothermal AFM-IR spectroscopy and installation of a Dimension IconIR system at imec on April 7, 2026. The initiative expands AFM-IR use beyond contamination analysis into EUV photoresist, transistor scaling materials, and nanoscale surface functionalization.
The collaboration is a Joint Development Project with imec to evaluate nanoscale chemical characterization, citing label-free chemical analysis with sub-5-nanometer resolution to support advanced semiconductor research.
Bruker (Nasdaq: BRKR) appointed Thierry L. Bernard to its Board of Directors effective April 1, 2026. Mr. Bernard is an experienced life‑science tools and diagnostics executive and current CEO of QIAGEN, who has led molecular diagnostics since 2015 and became CEO in 2019.
The company said he will support Bruker’s strategy across life‑science research, biopharma and diagnostics as it pursues profitable growth and margin expansion.
PreOmics and Biognosys (BRKR) announced a favorable PTAB decision: the U.S. Patent Trial and Appeal Board revoked central claims of U.S. Patent No. 11,435,360 (IPR2024-01473), including the sole independent Claim 1.
The patent is owned by The Brigham and Women’s Hospital and exclusively licensed to Seer; the revoked claim covered workflows using multiple nanoparticle types to form biomolecule coronas to detect proteins.
Bruker (Nasdaq: BRKR) launched CellScape XR, a next-generation spatial proteomics platform designed for diagnostic and prognostic assay development. The platform emphasizes quantitative performance, robustness, and high throughput, incorporating advances in optics, fluidics, and protocols to support translational and clinical studies.
Bruker cites collaborations at University Hospital Schleswig-Holstein, Kiel, where teams analyzed >1,000 clinically annotated samples and plan to expand to ~3,000 patient samples, illustrating CellScape XR's intended scalability for large clinical cohorts.
Bruker (Nasdaq: BRKR) is expanding its collaboration with Noetik to scale tissue foundational models using CosMx® Spatial Molecular Imager. The partnership follows a study of >3,500 patient samples and will add thousands more, aiming to train models on up to one billion spatially resolved human cells.
The work targets genome-wide, single-cell and subcellular spatial transcriptomic and multiomic datasets to support translational and therapeutic applications.